PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
July 7, 2009Annals of Internal Medicine

Effect of Telmisartan on Renal Outcomes

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does telmisartan improve composite renal outcomes in adults with high vascular risk who cannot tolerate ACE inhibitors?

Population

5,927 adults with known cardiovascular disease or diabetes with end-organ damage but without…

Comparison

Telmisartan, 80 mg/d plus standard treatment for… vs Matching placebo plus standard treatment.

Design

RCT, Randomly assigned by a central automated system, Participants and…

Follow-up

mean of 56 months

Authors

JMJohannes F.E. Mann

Discussion

Loading...

Member takes

Overview

Does not support telmisartan for renal protection in ACEI-intolerant high-risk patients; confirms neutral renal effects versus placebo.

Structured PICO

Does telmisartan improve composite renal outcomes in adults with high vascular risk who cannot tolerate ACE inhibitors?

P
Population
5,927 adults with known cardiovascular disease or diabetes with end-organ damage but without macroalbuminuria or heart failure who cannot tolerate angiotensin-converting enzyme inhibitors.
I
Intervention
Telmisartan, 80 mg/d plus standard treatment for a mean of 56 months.
C
Comparator
Matching placebo plus standard treatment.
O
Outcome
Composite renal outcome of dialysis or doubling of serum creatinine.composite

In adults with high vascular risk intolerant to ACE inhibitors, telmisartan did not significantly reduce the composite renal outcome of dialysis or doubling of serum creatinine compared to placebo.

Limitations

  • Only 17 participants had dialysis.

Cite This Study

Johannes F.E. Mann (2009) studied this question.

synapsesocial.com/papers/6a892b0d3fe85f489c1ff9cdhttps://doi.org/10.7326/0003-4819-151-1-200907070-00122
View Full Paper
Ask AI
Bookmark
Share